Evaluation of the clinical efficacy of maintenance chemotherapy for local advanced non-small cell lung cancer
10.3781/j.issn.1000-7431.2010.04.015
- VernacularTitle:局部晚期非小细胞肺癌维持化疗的疗效评价
- Author:
Xin HU
;
Guangming LI
;
Shimin WEN
;
Dacheng REN
;
Jun BIE
;
Rongqiang PAN
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cell lung;
Drug therapy;
Maintenance chemotherapy;
Vinorelbine;
Survival analysis
- From:
Tumor
2010;(4):343-346
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy of maintenance chemotherapy for patients who had local advanced non-small cell lung cancer (NSCLC) and was responsive to primary radiotherapy and chemotherapy. Methods:One hundred and twenty patients with stage ⅢA or ⅢB NSCLC received 4 cycles of chemotherapy combined with radiotherapy. The 63 patients who achieved certain remission were randomly divided into maintenance chemotherapy group(n=33) and control group(n=30). The patients in maintenance chemotherapy group (treatment group) received vinorelbine (20 mg/m2, d 1 and d 8, per 28 d a cycle) and those in control group were not given maintenance chemotherapy. The clinical efficacy, survival rate and adverse reaction of the two groups were evaluated. Results:There are a longer median time to progression(TTP) in treatment group compared with control group (8.5 month vs 5.0 month, P<0.05). The 1-and 2-year survival rates were 66.7% and 36.4% in the treatment group and 60.7% and 32.1% in the control group, respectively. The difference between the survival rates of two groups was not significant (P>0.05). Conclusion:Maintenance vinorelbine-based chemotherapy prolonged the median time to progression but had no effect on survival time in patients with local advanced NSCLC who responded to induction chemotherapy.
